Thymidylate synthase (TS) catalyses the only de novo pathway to produce thymidylate for DNA replication and repair and is an important target for cancer chemotherapy. Preexisting or acquired drug resistance in tumor cells limits clinical efficacy of TS-targeting drugs. Cells selected for higher TS protein activity have decreased sensitivity to TS-targeting chemotherapeutic agents (5-FUdR and raltitrexed). New therapeutic strategies are required to overcome treatment resistance. Among these, upregulation of drug resistance mediators in normal, nontarget cells and/or antisense downregulation of those mediators (alone or in combination with protein-targeting drugs) are candidate strategies. We have targeted human TS mRNA with antisense oligodeoxynucleotides (AS ODNs), complementary to the translation start site (TSS), the coding region, and the 3′ untranslated region. We report here that, in response to treatment with a novel TSS-targeting AS ODN 791, TS gene transcription in a human cervical carcinoma cell line (HeLa) was unexpectedly increased by 70%. Interestingly, the increased TS gene transcription and nuclear TS RNA did not elevate levels of total cellular TS mRNA, but did increase TS protein activity by 35% and TS protein level by 150%. Increased TS protein activity and level did not alter proliferation rate or sensitivity to TS-targeting drugs (5-FUdR or raltitrexed). To assess concentration-dependent effects of TS on sensitivity to TS-targeting drugs, incremental increases of TS protein levels were generated by transfection of a mammalian TS expression vector. Increases in TS protein of less than approximately 400% did not significantly affect sensitivity to TS-targeting drugs, while greater TS protein levels did. These data indicate that AS ODNs targeting TS mRNA can upregulate TS expression and activity in a manner dependent on the sequence being targeted, and that there exists a threshold increase (greater than approximately 400-700% in HeLa cells), required to initiate resistance to TS-targeting drugs.
INTRODUCTION
lular proliferation in human tumor cell lines grown in vitro and as xenografts in immunocompromised mice (5, (17) (18) (19) (Jason et al., submitted). In addition to sucThymidylate synthase (TS) is an essential enzyme that produces thymidylate (dTMP) from deoxyuridine cessful downregulation of TS mRNA and protein using AS, we have also reported that targeting the TS monophosphate (dUMP) by a reaction that is the sole intracellular pathway generating dTMP for DNA repmRNA translation start site (TSS) with AS RNA vectors and AS ODNs unexpectedly increased TS gene lication and repair (13). Because of the importance of dTMP in DNA precursor synthesis, TS is a target for transcription in HeLa cells (14) . Increased TS protein levels have been observed in a human colon tumor many chemotherapy agents including 5-fluorouracil (5-FU), 5-fluorodeoxyuridine (5-FUdR), raltitrexed, cell line (HT-29) in response to an 18-mer antisense ODN targeting the AUG of the TSS (24) , which, alpemetrexed, and others (10,13). 5-FU, since its development in the late 1950s, has been the standard treatthough gene transcription was not assessed in that study, is consistent with our observation of HeLa cell ment for colorectal cancer and is commonly used for treatment of head and neck, breast, and gastrointestiresponse to targeting the TSS with antisense reagents.
In the present study we show that treatment of nal cancers (25). TS is a negative prognostic marker for colorectal cancer and indicative of increased celHeLa cells with a novel TS AS ODN 791 (targeting the TSS) increased TS gene transcription (as mealular proliferation, tumor invasiveness, and metastatic capacity (34) . Despite the importance of TS as a mosured by increased TS nuclear RNA). Increased TS gene transcription occurred without increasing steadylecular target for anticancer therapy, response rates to 5-FU remain low (in the 10-30% range) (38). Develstate levels of TS mRNA in total cellular RNA. Increased TS transcription was accompanied by inopment of new and better agents to target TS or the dTMP pathway is required (21, 38) . A primary obstacreased TS protein and activity levels. The observed increase in TS protein following AS ODN 791 treatcle in the effectiveness of fluoropyrimidine chemotherapeutic agents is the development of resistance to ment did not mediate resistance to TS-targeting agents, nor did it alter proliferation rate, both of this class of TS-targeting drugs in tumor cells, through a variety of mechanisms, including (and of primary which have been reported to correlate with TS protein levels (1) . On the other hand, transfection of a mamimportance) elevated TS protein levels in tumors (7, 21) . Acquired or intrinsic drug resistance reduces malian TS expression vector to increase TS protein to higher levels than those achieved after treatment the clinical effectiveness of current anti-TS drugs (38), and tumor cell resistance to fluoropyrimidines with AS ODN 791 did enhance resistance to the TStargeting agent, raltitrexed. These data suggest that (5-FU, 5-FUdR) and other antimetabolites (raltitrexed, pemetrexed) is thought to be mediated by TS (1, 26) .
resistance to TS-targeting drugs requires a threshold level of increased TS protein, and indicate that inFor example, TS gene amplification, increased TS protein stability, and translational derepression (increases in TS protein levels (up to 700%) do not drive enhanced proliferation. creased TS mRNA translation after treatment with TS-targeting drugs due to drug-induced dissociation of TS from its own mRNA) all lead to increased TS protein levels and resistance to TS-targeting drugs MATERIALS AND METHODS (28,37). Variant TS proteins with lowered capacity to Cell Culture bind to TS-targeting drugs have been identified, and allow persistent TS activity and resistance to anti-TS HeLa cells were obtained from the American Type drugs (6) . Sensitivity of normal tissues to TS-targetCulture Collection (Manassas, VA). HeLa cells were ing drugs is also considered to be a major impedigrown in Dulbecco's modified Eagle's medium. All ment to TS-related therapy (33), and strategies to enmedia were supplemented with 10% fetal bovine hance TS expression in normal cells and/or selection serum (FBS). Cells were cultured at 37°C in a humidof patients for TS-targeted treatment on the basis of ified atmosphere of 5% CO 2 . Tissue culture reagents polymorphisms in individuals with elevated TS in were from Invitrogen Canada (Burlington, ON, normal tissues that enhance therapeutic indices have Canada). been proposed (8) .
We previously reported antisense oligodeoxynucleoOligodeoxynucleotides and Transfection Methods tides (AS ODNs) that target TS mRNA to decrease TS protein levels and overcome treatment resistance.
TS AS ODN 791 (5′-CGCGGTACGGACACCG GCCG-3′) is complementary to bases 101 to 120 Targeting the 3′ untranslated region (3′-UTR) and the coding region of the TS mRNA with AS ODNs dewithin the 5′-UTR and includes the translation start site of human TS mRNA. The following day, ODNs were mixed vitrogen) was followed by polymerase chain reaction with 0.5 µg/ml Lipofectamine 2000 (Invitrogen) in (PCR) using primers specific for GAPDH and TS as serum-free medium for 20 min, after which FBS (0.1 described previously (5) . PCR products were visualvolume) was added. The medium on the cells was ized on 1% agarose gels stained with ethidium brothen replaced with 2 ml of medium with ODN/lipid. mide. For real-time PCR amplification of TS, the Four hours later, a further 2 ml of growth medium PCR reaction mixture consisted of 600 nM human was added, and the cells were incubated for up to TS forward (5′-GGCCTCGGTGTGCCTTT-3′) and 4 days. Due to some inconsistencies in nonspecific human TS reverse (5′-GATGTGCGCAATCATG toxicity and antisense efficacy using Lipofectamine TACGT-3′) primers, 200 nM human TS probe (5′-6F 2000, some of the results (shown in Fig. 4 After 24 h cells were washed twice with PBS, and then 2 ml of medium with plasmid/lipid was scraped in cold PBS with a rubber policeman, and added to each flask. Four hours later, a further 2 ml centrifuged at 200 × g for 10 min. Cell pellets were of growth medium was added, and cells were inculysed in ice-cold lysis buffer; 20 mM Tris-HCl, pH bated for up to 4 days. 7.6, 0.1% SDS, 1% Triton X-100, 10 mM EDTA) for 30 min at 4°C. Lysates were centrifuged at 10,000 × Run-on Transcription Measurement g for 10 min and the supernatants collected. Protein concentrations were estimated using a BioRad protein HeLa cells were treated with the 100 nM ODN/ liposome solution for 24 h. Nuclei were isolated and assay kit (BioRad, Montreal, PQ). Proteins (40 µg per lane) were resolved on SDS-polyacrylamide run-on transcription was carried out after addition of reaction buffer {dGTP, dATP, dUTP, [ 32 P]-dCTP (12%) gels and transferred to Hybond membranes (GE Healthcare). The membranes were blocked in (GE Healthcare, Baie d'Urfe, PQ, Canada), 1 mM DTT} for 30 min at 37°C. Radiolabeled RNA was 5% skim milk powder in TBS-Tween (1 h at room temperature), and incubated for 2 h with rabbit antiisolated following TRIzol protocol (Invitrogen). Probes specific for TS, glyceraldehyde 3-phosphate human TS polyclonal antibody (the generous give of Dr. Masakazu Fukushima, Taiho Pharmaceuticals, dehydrogenase (GAPDH), and 18S were immobilized on a Hybond-N membrane (GE Healthcare) and preTokushima Research Center, Hanno-City, Japan) followed by rabbit anti-actin antibody (Sigma) for 1 h. hybridized for 1 h. Radiolabeled RNA was added to Proteins were visualized using horseradish peroxi-RESULTS dase-labeled anti-rabbit antibody and enhanced ECL-AS TS ODN 791 Induces TS Gene Transcription Plus (GE Healthcare). Intensity of bands was quantitated using AlphaEaseFC software. To quantitate TS
We have previously reported that antisense targetprotein activity, a H]FdUMP binding assay was ing of TS mRNA sequences within and proximal to used, as described previously (17) . Total protein (30 the TS mRNA TSS, but using antisense reagents µg) was electorophoresed on a 12% polyacrylamide (ODN 90 and pAS/TSS) complementary to segel as described above. Gels were stained with Cooquences other than those specifically targeted by massie blue (2.5 g Coomassie brilliant blue, 45%
ODN 791 ( Fig. 1) , increased TS gene transcription methanol, 45% H 2 O, 10% acetic acid) for 1 h with (as reflected in increased nuclear TS RNA, including shaking at 25°C, washed twice in distilled water, and TS RNA with and without intron sequences) without destained (10% acetic acid, 40% methanol) with concomitant increase in steady-state, total cellular, shaking at 25°C. Densitometer scanning was permature TS mRNA (14) . formed to determine the total amount of blue staining
Treatment of HeLa cells with AS TS ODN 791 in each lane (where staining indicated the amount of (100 nM), a 20-mer AS ODN complementary to the total protein). The relative amount of total protein in AUG translation start site (TSS) and sequences 5′ and each lane was determined by dividing the densitomet-3′ to the TSS ( Fig. 1 ), increased TS gene transcripric volume of each lane by the cumulative densitotion (relative to GAPDH gene transcription) by 77 ± metric volume of all compared lanes.
13.9% compared to cells treated with scrambled control ODN 25, at 24 h posttransfection with antisense and control ODNs (Fig. 2) . The increase in TS gene Growth and Drug Sensitivity Assay transcription relative to transcription from an alternative comparitor (18S rRNA genes) was similar (71 ± Cells were treated with ODNs (50 nM) as de-5.2%) and increased confidence in the validity of the scribed above. After 4 days cells were removed from observation. These data confirmed our earlier rethe flasks by trypsin treatment, and counted in saline ported observation (14) as a basis for further investisolution using an electronic particle counter (Beckgation of the consequences of increased TS transcripman Coulter, Hialeah, FL). For drug sensitivity tion for TS mRNA and protein levels, and effects on assays, cells were treated with ODN (50 nM) as drug sensitivity. above. After the initial 4-h ODN treatment, the apIt was not known whether total cellular mRNA levpropriate concentration of drug was added. For plasels were unaltered, as was the case when targeting mid treatment drug sensitivities, drug was added 24 with other antisense reagents that included sequences h after transfection. Proliferation is expressed relative complementary and/or proximal to the TSS (14) . To to treatment with control ODN 25 or ODN 791 in the address this question, TS mRNA levels were assessed absence of drug (Fig. 6) mRNA levels, it was not known whether enhanced TS gene transcription resulted in increased TS protein levels or activity. To address this question, TS proStatistical Analysis tein levels were measured 24 h after transfection with AS TS ODN 791. ODN 791 (100 nM) induced a 37 ± Statistical significance was determined using Student's t-test. All experiments were performed at least 10% increase in relative TS protein levels (i.e., relative to β-actin protein) (Fig. 4A ) compared to cells two times. treated with scrambled control ODN 25 (as measured tive to β-actin. The increased TS level was accompanied by a 37 ± 18% increase in TS protein activity by immunoblot). There were no significant differences in total protein levels among compared lanes (as measured by a H]FdUMP in vitro TS binding assay to assess the capacity of TS protein to associate (Fig. 5) , confirming the observed increase in TS relawith radiolabeled FdUMP substrate) (Fig. 4B) .
Increased TS protein and TS activity are associated with enhanced proliferation and resistance to TStargeting drugs (1, 29) , and specific downregulation of TS leads to repressed proliferation and accumulation of cells at cell cycle checkpoint stages (5) and decreased resistance to TS-targeting drugs (17, 18) . To determine whether the increased level and activity of TS after treatment with AS TS ODN 791 was sufficient to alter HeLa cell sensitivity to chemotherapeutic drugs targeting TS (raltitrexed and 5-FUdR), and one that does not (cisplatin), the capacity of pretreatment of HeLa cells with control ODN or AS TS ODN 791 to alter tumor cell growth was assessed. AS TS ODN 791 treatment, at concentrations that significantly increased TS (100 nM), had no effect on the capacity of HeLa cells to increase in number over a 4-day growth period in culture (Fig. 6A) nor did it alter the number of cells in G 1 , S, or G 2 /M phases of cell cycle (Fig. 6B) . Furthermore, AS TS ODN 791 treatment (sufficient to induce TS protein level and activity) did not affect the sensitivity of HeLa cells to raltitrexed (Fig. 7Aii) or at concentrations higher than those that increased TS protein and TS gene transcription (150 and 200 nM) (Fig. 7Aiii, Aiv) . There was no change in the sensitivity of HeLa cells to 5-FUdR, raltitrexed, or cisplatin at concentrations lower (50 nM) than those that resulted in increased TS (Fig. 7Ai, Bi, Bii) . Thus, increased TS resulting from treatment with antisense ODNs targeting the TS mRNA TSS did not affect cell cycle distribution and drugs suggests that enhanced TS levels achieved by other means might modulate these events and, consequently, provide a system to compare with antisensemediated TS upregulation. We therefore transiently transfected HeLa cells with TS-14 (a plasmid directing expression of TS) to generate cells with TS protein levels enhanced between fourfold (mediated by 1.5 µg plasmid transfected into 3 × 10 5 cells) and sixfold (mediated by 6 µg plasmid transfected into 3 × 10 5 cells), compared to cells transfected with TIED [a plasmid directing expression of TIED, the expression of which is known to be irrelevant to sensitivity to cytotoxic drugs and proliferation (4)]. The trans- sensitivity to the non-TS-targeting drug cisplatin (Figs. 8C, 9B ).
DISCUSSION
Thymidylate synthase is well recognized as an appropriate target for cancer treatment (20) and current TS-targeted treatments have positive effects on human tumors and cancer survival. However, there is need for improvement. To increase anti-TS effectiveness, new TS-targeting agents, including raltitrexed, pemetrexed, and Thymitaq, have been developed. Changes in dose and timing of administration have been explored and implemented (35, 38) . Several physiological events, including resistance of tumor cells and sensitivity of normal cells to therapy, continue to be barriers to effectiveness of TS-targeting drugs, and improved strategies to overcome drug re- fection efficiency of the different doses of plasmid was similar, as verified by cotransfection of equal amounts of a β-galactosidase expression vector followed by measurement of β-gal levels (data not shown).
HeLa cells transfected with TS-14 had significantly increased TS (compared to control cells transfected with TIED) when the dose of plasmid was 0.5 µg or greater: 0.25 µg of plasmid had no effect on TS levels (Fig. 8A) . HeLa cell resistance to raltitrexed was unchanged in cells transfected with 0.25 µg of TS-14 (which did not increase TS protein levels). Cells transfected with 0.5 µg of TS-14 plasmid had significantly increased TS protein levels (Fig.  8A ), but the increase was insufficient to increase sistance and circumvent toxicity to normal cells are lated HeLa cell nuclei, relative to either GAPDH or 18S rRNA gene transcription, compared to cells needed (9) .
We have reported that, although AS ODNs targettreated with a scrambled control AS ODN 25 (Fig.  2) . Interestingly, the increased nuclear TS RNA ining some TS mRNA regions reduce TS mRNA and protein and enhance sensitivity to TS-targeting drugs duced by ODN 791 did not lead to an increase in total cellular TS mRNA (Fig. 3) . The mechanism un-(2,3,5,17-19), targeting TS mRNA at or near the translation start site increases TS gene transcription derlying the disparity is not known, but several possibilities may be relevant. First, the hybridization ( Fig. 1) (14) . To explore unexpected antisense-mediated enhancement of TS gene activity we treated method used to detect nuclear TS mRNA in the present study does not discriminate between unprocessed, HeLa cells with AS TS ODN 791 (targeting the TSS) (Fig. 2) . This increased TS gene transcription in isoimmature TS RNA and mature TS mRNA, while the RT-PCR methods used to measure total cellular RNA detect only mature TS mRNA. Thus, ODN 791-mediated increased TS gene transcription might enhance the level of nuclear TS RNA products without increasing mature TS mRNA. Alternatively, mRNA translation has been functionally linked to mRNA degradation in yeast (31) and in HeLa cells (12) . If increased TS gene transcription is accompanied by increased TS mRNA that undergoes concurrent translation and degradation, then increased TS protein and TS gene transcription against a background of apparently unchanged overall TS mRNA would be expected. In fact, this is the pattern we observed: increased TS gene transcription following AS TS ODN protein levels and activity.
A stem-loop structure thought to be a binding site tivity to mediate enhanced TS-targeting drug resistance has not been reported, but evidence of a refor TS protein that encompasses the TSS of TS mRNA has been proposed, based on recognition that quirement for a threshold level of other endogenous proteins to mediate a detectable increase in drug complementary sequences flanking the TSS are expected to hybridize to generate a loop containing the resistance does exist. Aldehyde dehydrogenases (specifically, ALDH1A1 and ALDH3A1) mediate sen-TSS (28). TS protein/TS mRNA association at the TSS has been confirmed, and binding of TS protein sitivity to cyclophosphamide and other oxazaphosphorines used to treat breast cancer (36) . High to its substrates or TS-targeting drugs leads to dissociation of TS protein from mRNA and increased ALDH1A1 and ALDH3A1 levels have been reported to predict resistance to cyclophosphamide, but the translation (11, 28) . AS TS ODN 791 is complementary to sequences within the stem and, if bound to correlation is not apparent at lower ALDH levels in human breast tumors: an observation that has been those sequences, could interfere with stem-loop formation. If so (and if AS TS ODN 791 binding did suggested as evidence that the lower levels are below a threshold level necessary to mediate cyclophosphanot appreciably reduce functional association of the translation machinery with TS mRNA), the result mide resistance (36) .
To assess whether lower levels of TS fell below a could be reduced TS protein binding, enhanced translation, and increased TS protein levels. The possibilthreshold necessary to mediate resistance to TS-targeting drugs, HeLa cells transfected with increasing ity of antisense-mediated enhancement of translation is in agreement with our observation of increased TS amounts of TS-14 expression vector were assessed for increased TS protein levels and enhanced sensiprotein levels in cells in the absence of increased TS mRNA, and is being actively investigated in our labtivity to raltitrexed. Transfection of 0.25 µg TS-14 into HeLa cells neither increased TS protein levels oratory.
Overall, and regardless of mechanism, increased nor enhanced resistance to raltitrexed. However, transfection of 1.5 or 2.0 µg TS-14 both increased TS gene transcription resulted in increased TS protein and TS protein activity. The question of whether the TS protein levels and enhanced raltitrexed resistance. Interestingly, transfection with intermediate amounts increased levels affected physiological events known to be associated with increased TS function remained.
of TS-14 (0.5 and 1.0 µg) significantly increased TS protein but had no effect of sensitivity to raltitrexed Increases in TS protein levels in tumor cell lines and in normal rat tissues have been reported to accom- (Fig. 8) . The enhanced resistance was specific to the TS-targeting raltitrexed, with no change in resistance pany increased proliferation rate and accumulation of cells in G 1 /S of the cell cycle (15, 22, 30, 32, 34) . Furto cisplatin: an observation consistent with our reports (17,18) of antisense-mediated downregulation thermore, an approximately 200% increase in TS protein activity in a human colon tumor cell line (HT29) of TS increases sensitivity to TS-targeting but not TS non-targeting drugs. treated with antisense ODN targeting the TSS has been reported to enhance resistance to 5-FUdR (24) .
An inducible TS expression system has been reported to increase TS protein levels in a human breast We assessed the capacity of AS TS ODN 791 treatment to alter HeLa cell proliferation and/or accutumor cell line (MDA-435) by approximately sixfold, and to concomitantly increase resistance to 5-FU and mulation of cells in different cell cycle compartments. Although AS TS ODN 791 increased TS proraltitrexed (29) . In that study, increased TS had no effect on proliferation rate or cell cycle, consistent tein activity by approximately 35% (Fig. 4B ) and TS protein level by approximately 37% (Fig. 4A) , there with the lack of effect on cell cycle and proliferation in response to TS-14-mediated increased TS in HeLa was no effect on proliferation (Fig. 6A) or distribution into cell cycle compartments (Fig. 6B) . In addicells (Fig. 6) . A threshold level of TS mRNA in colorectal tution, AS TS ODN 791 treatments that elicited the same increase in TS protein level and activity had mors in patients [(TS mRNA)/(β-actin mRNA) > 4.1 × 10 3 ] has been recognized as a predictor of lack of no effect on sensitivity of HeLa cells to a range of concentrations of the TS-targeting drug raltitrexed response to treatment with 5-FU (16, 26, 27) . However, the heavy reliance of TS regulation on posttran- (Fig. 7B ) and non-TS-targeting cisplatin (Fig. 7C) . The lack of capacity of increased TS to enhance rescriptional events reduces the strength of the correlation between TS mRNA and protein, and the sistance to TS-targeting drugs is qualitatively at odds with the observation of increased resistance to 5-reliability of TS mRNA measurement as a surrogate for TS protein and TS activity measurement. To our FUdR after antisense induction of increased TS activity (24) , but suggests that a threshold TS activity is knowledge, our observation of a threshold level of TS protein required to mediate resistance to TS-targeting necessary to mediate resistance.
A necessary minimum increase in TS enzyme acdrugs is the first such report. We believe that this AS ODNs TO TS mRNA INDUCES TRANSCRIPTION AND PROTEIN 237 resistance to TS-targeting drugs: an observation that we have further extended to reveal that a threshold level of TS protein appears to be necessary to initiate resistance to TS-targeting drugs (Fig. 10) . Furthermore, and in spite of the association of increased cellular TS levels with proliferation and the G 1 /S compartment of cell cycle, increased TS protein levels in response to transfection of AS TS ODN 791 or the TS expression vector TS-14 had no effect on proliferation or the fraction of cells in different cell cycle compartments, even when those levels were sufficient to mediate resistance to TS-targeting drugs. Overall, the phenomenon of antisense-mediated 
